Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMKWGS1)

Drug Name
PBT-2 Drug Info
Synonyms AD/HD therapy, Prana; Alzheimers/Huntingtons disease therapy (chelating agent), Prana
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Phase 2 [1]
Huntington disease 8A01.10 Phase 2 [2]
Cross-matching ID
PubChem CID
10016012
CAS Number
CAS 747408-78-2
TTD Drug ID
DMKWGS1

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Microtubule-associated protein tau (MAPT) TTS87KH TAU_HUMAN Modulator [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Microtubule-associated protein tau (MAPT) DTT MAPT 3.621 4 5.418 2.868
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Alzheimer disease
ICD Disease Classification 8A20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Microtubule-associated protein tau (MAPT) DTT MAPT 3.76E-06 -0.22 -0.6
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01590888) Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis. 2010;20(2):509-16.